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Histone modifications have been implicated in stem
cell maintenance and differentiation. We have
analyzed genome-wide changes in gene expression
and histone modifications during differentiation of
multipotent human primary hematopoietic stem
cells/progenitor cells (HSCs/HPCs) into erythrocyte
precursors. Our data indicate that H3K4me1,
H3K9me1, and H3K27me1 associate with enhancers
of differentiation genes prior to their activation and
correlatewithbasal expression, suggesting that these
monomethylations are involved in themaintenance of
activation potential required for differentiation. In
addition, although the majority of genes associated
with both H3K4me3 and H3K27me3 in HSCs/HPCs
becomesilent and loseH3K4me3after differentiation,
those that lose H3K27me3 and become activated
after differentiation are associated with increased
levels of H2A.Z, H3K4me1, H3K9me1, H4K20me1,
and RNA polymerase II in HSCs/HPCs. Thus, our
data suggest that gene expression changes during
differentiation are programmed by chromatin modifi-
cations present at the HSC/HPC stage and provide
a resource for enhancer and promoter identification.
INTRODUCTION
The adult hematopoietic system consists of multiple distinct
blood cell lineages and is continuously regenerated from
common hematopoietic stem cells (HSCs) under normal condi-
tions or following bone marrow transplantation (Morrison et al.,
1995). While a stable pool is maintained by self-renewal, the
multipotent HSCs continuously differentiate to produce a large
number of blood cells. It remains unclear how the balance
between self-renewal and differentiation is controlled and how
a decision for differentiation is specified at molecular levels.
However, it is clear that transcription programs, which include
both activation of genes involved in the target lineage and repres-
sion of genes involved in nontarget lineages, play essential roles80 Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc.during this process of fate determination (Surani et al., 2007).
These specific transcription programs are controlled by a close
coordination between transcription factors andchromatin states,
both of which are regulated by extracellular signals. Appropriate
chromatin modifications, including histone modifications, can
help to maintain a relatively stable expression pattern of either
activation or repression in stem cells or terminally differentiated
cells. Indeed, enzymes that modulate chromatin structure,
including Brg1 and Ezh2, have been implicated in regulating
embryonic development and embryonic stem cell (ESC) function
(reviewedbySurani et al., 2007), and changes in chromatin struc-
ture have been reported during differentiation of ESCs (Bernstein
et al., 2005; Chambeyron and Bickmore, 2004; Mikkelsen et al.,
2007; Mohn et al., 2008) and other cells such as T cells and red
blood cells (Ansel et al., 2006; de Laat et al., 2008).
Previous studies have provided genome-widemaps of histone
modifications H3K4me3 and H3K27me3 in ESCs (Bernstein
et al., 2006; Mikkelsen et al., 2007; Pan et al., 2007; Zhao
et al., 2007). Many critical regions involved in pluripotency and
differentiation of ESCs are associated with both H3K4me3 and
H3K27me3 modifications and are termed ‘‘bivalent domains’’
(Bernstein et al., 2006). The relative levels of these two modifica-
tions can effectively discriminate genes that are expressed or
repressed in ESCs (Mikkelsen et al., 2007) and human CD4+
T cells (Barski et al., 2007; Roh et al., 2006). Regions with both
H3K4me3 and H3K27me3 modifications have been proposed
to play critical roles and can be resolved to monovalent modifi-
cation in ESC differentiation (Azuara et al., 2006; Bernstein
et al., 2006; Mohn et al., 2008). However, it is not clear what
controls the fate choice of bivalent genes.
CD34+ or CD133+ cells from human bone marrow or periphery
blood contain HSCs that can sustain long-term hematopoiesis
after transplantation (Morrison et al., 1995; Yin et al., 1997).
These cells can be differentiated into particular cell types
in vitro under defined conditions. The best characterized path-
ways for in vitro differentiation of the CD34+ or CD133+ cells
are the production of erythrocyte precursor cells, which can be
further induced to mature red blood cells (Giarratana et al.,
2005). Even though the mechanisms of hematopoietic differenti-
ation are still not fully clear, it is known that extensive reorganiza-
tion of chromatin structure at critical loci occurs during the
process (de Laat et al., 2008; Litt et al., 2001), which is regulated
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including both transcription factors and chromatin-modifying
enzymes. Only limited chromatin regions have been analyzed
during the differentiation of HSCs into erythrocyte cells, and it
is therefore important to investigate the global changes of
chromatin modifications during such a process. However,
almost any stem cell population isolated from humans, including
the CD34+ or CD133+ HSCs, is complex and composed of
multiple progenitors with different differentiation potentials.
While considerable efforts have been put into developing tech-
niques to prospectively isolate subpopulations, the best proce-
dures yield a relatively complex mixture of cells and a very low
number of cells. Another challenge is that these cells do not
self-renew in culture and are therefore in limiting quantities.
Even with these limitations, the CD34+ and CD133+ cells isolated
from human bone marrow or periphery blood have demon-
strated clinical efficacy in transplantation therapies (Bitan et al.,
2005) and are therefore widely used in treatment of various
hematological disorders. It is therefore crucial to understand
the epigenetic states of these important cells. Investigation of
the global patterns of chromatin modification in these cells can
provide valuable information and help us understand the differ-
ences between HSCs/HPCs with hESCs andmore differentiated
hematopoietic cells and may provide clues for designing better
therapeutic strategies. We have therefore examined the
genome-wide distribution of chromatin modifications in the
human HSCs/HPCs and differentiated erythrocyte precursor
cells. Our data indicate that differentiation of CD133+ cells into
CD36+ cells is accompanied by dramatic changes of histone
modifications at critical genetic regions. Even though both
H3K27me3 and H3K9me3 have been implicated in gene repres-
sion, we find that they are correlated with silencing different
subsets of genes. Our data indicate that, while a small fraction
of bivalent genes in HSCs/HPCs lost H3K27me3 after differenti-
ation, themajority of the bivalent genes lost H3K4me3. The asso-
ciation of increased levels of H3K4me1, H3K9me1, H2A.Z, and
RNA polymerase II (Pol II) with the bivalent genes indicates the
potential of their losing H3K27me3 and becoming transcription-
ally active during differentiation. These results suggest that the
choice of resolution of bivalent modifications during differentia-
tion is already programmed at the HSC/HPC stage.
RESULTS
Experimental Design
Mobilized CD133+ cells were purified from human periphery
blood lymphocytes (PBLs) using established protocols (Migliac-
cio et al., 2002). To better characterize the composition of the cell
populations, we stained the cells for the presence of various
surface markers. Human HSCs are characterized by high levels
of CD34 and CD133 expression, intermediate levels of CD117
(c-kit) and CD90 (Thy-1), and no or low levels of CD38, HLA-
DR, and CD71 (Szilvassy, 2003). Indeed, we found high levels
of CD34 and CD133 expression in more than 98% of the cells
and CD117 and CD90 expression in a small fraction (2%–20%)
of the cells, consistent with these cells being stem cells or
progenitor cells (Figure 1A). However, more than 99%of the cells
were CD38, HLA-DR, and CD71 positive, indicating that the vast
majority of these cells were early progenitor cells.We differentiated the CD133+ cells to CD36-expressing cells,
which are precursor cells of erythrocytes (Figure 1B), using an es-
tablished protocol (Wong et al., 2008). FACS analysis confirmed
that more than 98% of the CD133+ cells expressed high levels of
CD34 and no detectible levels of CD36 (Figure 1C). After differen-
tiation, more than 95% of the cells expressed CD36 with the
concurrent disappearance of CD34 expression (Figures 1A and
1C). At the same time, CD117 increased from 2.12% in CD133+
cells to 87.25% in CD36+ cells, whereas CD38 and HLA-DR
decreased to 15.96% and 17.12%, respectively, after differenti-
ation (Figure 1A).
To examine the changes of chromatin modifications before
and after differentiation, we fragmented the chromatin from
CD133+ and CD36+ cells using micrococcal nuclease (MNase)
digestion and performed ChIP-Seq analysis for histone methyla-
tion (H3K4me1, H3K4me3, H3K9me1, H3K9me3, H3K27me1,
H3K27me3, H3K36me3, and H4K20me1) and histone variant
H2A.Z, as described previously (Barski et al., 2007). The distribu-
tion of RNA Pol II was also determined using ChIP-Seq. To test
the reproducibility of the modification patterns, we repeated
the ChIP-Seq analyses for H3K4me1 and H3K27me1 in both
CD133+ and CD36+ cells. Our results indicate that all the major
peaks of these modifications are reproducible (see Figure S1
available online).
Global Chromatin-Modification Patterns
in CD133+ and CD36+ Cells
To identify genomic regions associated with various histone
modifications, we searched for regions enriched for modifica-
tions using a statistical model (see the Supplemental Data for
details). Our data indicate that the distribution of modification
islands varied dramatically among different modifications. For
example, 65% and 73% of the H3K4me3 islands were found
in the promoter regions in CD133+ and CD36+ cells, respec-
tively, whereas 71%–76% of the H3K9me3 islands were de-
tected in the intergenic regions with less than 1% in promoter
regions (Figure 1C; Table S1). Other modifications including
H3K4me1, H3K9me1, H3K27me1, H3K36me3, and H4K20me1
were mainly detected in the transcribed regions (Figure 1C;
Table S1). We then compared directly the distribution profiles
of the modification islands for 20,444 known genes and found
that the overall patterns of modifications were very similar
between CD133+ and CD36+ cells (Figure S2). Interestingly,
the number of promoters associated with H3K9me1 decreased
from 52% in CD133+ cells to 25% in CD36+ cells; the promoters
associated with H3K27me1 decreased from 27% to 8%,
while the association with other modifications was similar
(Figure S3).
Correlation between Chromatin Modification and Gene
Expression in Each Cell Type
To analyze the relationship between chromatin modification and
gene expression in each cell type, we examined the mRNA
expression profiles in CD133+ and CD36+ cells, using gene
expression microarrays. From a total of 20,444 known genes
with corresponding probes on the arrays, 10,130 (50%) and
9,502 (46%) were unambiguously expressed in CD133+ and
CD36+ cells, respectively. To test how the modification level,
which is indicated by the number of reads in a region, correlatesCell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc. 81
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Figure 1. Differentiation of CD133+ Cells into CD36+ Cells
(A) Cell surface markers on CD133+ and CD36+ cells. The cells were stained using specific antibodies indicated on the left column and analyzed by flow
cytometry. The fractions of cells exhibited positive staining for each antibody are indicated.
(B) Experimental scheme.
(C) FACS analysis of the CD34 and CD36 expression levels before (upper panel) and after (lower panel) differentiation.
(D) The genome-wide distribution of different modifications. Total numbers of islands in promoter, gene body, and intergenic regions were identified for each
modification (see the Experimental Procedures for details). The graph shows the fraction of islands in each different region for each modification in CD133+
and CD36+ cells.with gene expression level, we plotted the modification levels
against the expression levels in the promoter and gene body
regions for CD36+ cells (Figure 2). This analysis indicates that
a positive correlation exists between gene expression and
H3K4me3, H3K4me1, H3K9me1, H3K36me3, and H4K20me1
for both promoters and gene body regions, which is consistent
with our observations in CD4+ T cells (Barski et al., 2007). It
appears that H2A.Z in the gene body region positively correlated
with expression for less-active genes but negatively correlated
with expression for more-active genes. H3K27me1 showed
a similar trend with H2A.Z, but the turning point for correlation82 Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc.was much higher. Similar results were obtained for CD133+ cells
(data not shown).
Both H3K9me3 and H3K27me3 have been implicated in gene
repression. Indeed, both of them were associated with genes
expressed at low levels. H3K27me3 negatively correlated with
the genes showing low and intermediate levels of expression.
In contrast, H3K9me3 negatively correlated with expression for
genes with higher expression levels (Figure 2B). Interestingly,
these genes were not associated with H3K27me3, suggesting
that H3K9me3 and H3K27me3 may modulate expression of
different subsets of genes (Figure 2B).
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Figure 2. Correlation between Histone Modification and Gene Expression in CD36+ Cells
Genes were grouped to 100 gene (one dot in the figure) sets according to expression level. The histone modification levels in promoter (A) and gene body (B)
regions were calculated for the same 100 gene sets (see the Experimental Procedures for details). The y axis indicates the histone modification level, and the
x axis indicates the expression level.Genome-wide Gene Expression Changes Reveal
Differentiation to Erythrocyte Lineage and Inhibition
of Other Lineages
Differentiation ofmouseHSCs to specific hematopoietic lineages
is associated with distinct gene expression patterns (Chambers
et al., 2007). To identify the specific expression patterns in human
HSCs and the differentiated erythrocyte precursor cells, we
examined their expression profiles and found 1041 genes upre-
gulated and 1697 genes downregulated more than 4-fold upon
differentiation into CD36+ cells (Table S2). Gene ontology anal-
ysis of downregulated genes indicated that the top biologicalprocesses associated with these genes were related with
immune responses or cellular defenses against pathogens (Fig-
ureS4A). For example, among thedownregulated genes, IFITM1,
IFITM2, IFITM3,GBP1,OAS1,OAS2, and IFNGR1 are involved in
interferon-mediated cellular defense systems, while IL16, LCK,
IL15, LAT2, LY75, CIITA, IL6R, and BCL2 contribute to the func-
tions of T, B, or NK cells. In contrast, many genes strongly
induced in CD36+ cells were involved in oxygen transport
(Figure S4A), which is among the functions of erythrocytes,
consistent with CD36+ cells being precursors of erythrocytes.
For example, several hemoglobin genes, including HBD, HBZ,Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc. 83
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lated genes.
Transcription factors play essential roles in the maintenance
and differentiation of stem cells. Our gene profiling analysis
revealed that 1328 and 1290 transcription factors (see the Exper-
imental Procedures for definition) were expressed in CD133+
and CD36+ cells, respectively. Among these, 218 transcription
factors were unique to CD133+ and 38 unique to CD36+ cells
(Table S3). In addition, although expressed in both cell types,
38 transcription factors were upregulated and 53 were downre-
gulated in CD36+ cells more than 3-fold. Among these transcrip-
tion factors, the members of Hox gene family, which encode
homeodomain-containing transcription factors and play critical
roles during development (Krumlauf, 1994), exhibited the most
dynamic regulation. Our analysis indicated that fiveHoxA genes,
including HoxA3, HoxA5, HoxA7, HoxA9, and HoxA10, were ex-
pressed in CD133+ cells andwere downregulated 15- to 137-fold
upon differentiation into CD36+ cells asmeasured byDNAmicro-
array analysis (Figure S4B), which was also confirmed using
qPCR assays (Figure S4D). Among the five HoxB genes ex-
pressed in CD133+ cells, HoxB2 was upregulated, whereas
HoxB6 was silenced during the differentiation (Figure S4C).
GATA3, a zinc-finger transcription factor known to be required
for T cell development and differentiation (Ting et al., 1996),
was silenced in CD36+ cells. Several transcription factors,
including IRF1, STAT1, and STAT2 involved in interferon-medi-
ated cellular defense system, were also downregulated. The
expression of PBX1, a homeodomain transcription factor
required for NK and B cell development (Sanyal et al., 2007),
decreased approximately 7-fold in CD36+ cells. In contrast, the
erythroid Kruppel-like factor (EKLF or KLF1) and GATA1, which
control the development and differentiation of erythroid lineage
(Donze et al., 1995; Takahashi et al., 1997), were upregulated
28- and 19-fold, respectively. These data collectively indicate
that the HSCs/HPCs were efficiently differentiated into the
erythrocyte-committed cells.
Dynamic Changes of ChromatinModifications at Critical
Loci-Encoding Transcription Factors
Our analysis of the histone modification patterns indicates that
differentiation of the HSCs/HPCs into CD36+ cells induced
a broad change in histone modifications in theHox gene clusters
(Figures 3A and 3B and Figure S5). TheHoxA genomic locus was
characterized by high levels of H3K4me3, H3K4me1, H3K9me1,
H3K36me3, H4K20me1, and H2A.Z in the center region contain-
ing A5, A6, A7, A9, and A10, bracketed by high levels of
H3K27me3 at both sides of the locus in CD133+ cells (Figure 3A,
left panels). This regionwasassociatedwith high levels of expres-
sion of A5, A7, A9, and A10 (Figure S4B). In CD36+ cells, the
H3K27me3 modification spread to the center region (highlighted
region in Figure 3A, right panel) (see Figure S6 for higher resolu-
tion display) with increased H3K9me3 signals in the right half of
the domain, while other ‘‘active’’ modifications disappeared.
These epigenetic changes were associated with silencing of all
HoxA genes (Figure S4B). The HoxB locus behaved differently
(Figure 3B). The region containing HoxB2–B6 was associated
with H3K4me3 and other marks indicative of active transcription
inCD133+cells,whereas the regioncontainingHoxB7–B13asso-
ciated with H3K27me3. However, the H3K27me3 signal spread84 Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc.to the HoxB5 and HoxB6 genes (B6 promoter highlighted in red)
with concurrent decrease of H3K4me3 signals in the same region
upon differentiation into CD36+ cells, which is consistent with the
repression of HoxB5 and HoxB6 genes (see Figure S7 for higher
resolution display). Unexpectedly, we also detected a striking
decrease of H3K4me1, H3K27me1, H3K9me1, and H4K20me1
signals at HoxB2, -B3, and -B4 genes, even though the
H3K4me3 and Pol II signals did not show much change in the
same region. The HoxC and HoxD genomic loci associated with
high levels of H3K27me3 and almost no active modifications in
both CD133+ and CD36+ cells (data not shown), consistent with
the silent state of these two loci. The KLF1 (EKLF) and GATA1
genes also exhibited dramatic changes of chromatin modifica-
tion (Figure S8), which is consistent with their strong induction
in CD36+ cells.
Dynamic Changes of Chromatin Modifications
of Cell Surface Marker Genes
As shown in Figure 1, the CD34 gene was highly expressed in
CD133+ cells and became silent in CD36+ cells. Our data indicate
that, in CD133+ cells, the activeCD34 gene promoter associated
with high levels of H3K4me3 and H2A.Z, while the gene body
region associated with widespread signals of H3K4me1,
H3K9me1, H3K27me1, H3K36me3, and H4K20me1 modifica-
tions (Figure 3C, left panel). High levels of Pol II were also de-
tected throughout the gene. In contrast, these signals either
decreased (H3K4me1 and H3K27me1) or disappeared
(H3K4me3, H3K9me1, H3K36me3, and H4K20me1) in CD36+
cells, while H3K27me3 was elevated in the promoter region (Fig-
ure 3C, right panel). Interestingly, H2A.Z signals decreased in the
promoter region and increased in the gene body of the CD34
genewhen it became silent in CD36+ cells. The histonemodifica-
tions in the CD133 gene exhibited similar changes to that in the
CD34 gene during differentiation (Figure S9). In contrast to the
CD34 and CD133 genes, the CD36 gene was silent in CD133+
cells and became highly active in CD36+ cells. The silent CD36
gene promoter associated with high levels of H3K4me1 and
H3K27me1, but not any detectible levels of H3K4me3 in
CD133+ cells (Figure 3D, left panel). As expected, high levels of
H3K4me3 were detected in the promoter region, and high levels
of H3K4me1, H3K9me1, H3K36me3, and H4K20me1 were
detected in the transcribed region in CD36+ cells (Figure 3D,
right panel). It is interesting to note that, although H3K4me1,
H3K9me1, and H3K27me1 marked the promoter region
upstream of the first exon of the CD36 gene in CD133+ cells,
the actual transcription may initiate from the second exon, as
suggested by the H3K4me3 and Pol II binding signals as well
as the distribution of H3K9me1, H3K36me3, and H4K20me1
modifications (Figure 3D, right panel). These data indicate that
dramatic epigenetic changes accompanied the changes in
expression states of these marker genes during differentiation
of HSCs/HPCs to erythrocyte precursor cells.
Correlation between the Dynamic Changes
of Chromatin Modification and Gene Expression
during Differentiation
To test how the dynamic changes of thesemodifications correlate
with gene expression change on a global level, we compared
directly the changes of expression with the changes of histone
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Figure 3. Changes in Histone Modifications Accompany Changes in Gene Expression during Differentiation
(A) Histone modification profiles in the HoxA locus (chr7:27,054,903-27,243,612) in CD133+ and CD36+ cells. The data are displayed as custom tracks on the
UCSC genome browser. The positions of the HoxA genes are indicated below the panel. The y axis shows the number of sequence reads detected in 200 bp
windows, and the x axis shows the chromosome coordinates in the genome.
(B) Histone modification profiles in the HoxB locus (chr17:43,931,826-44,203,425) in CD133+ and CD36+ cells. The positions of the HoxB genes are indicated
below the panel. The promoter region of the HoxB6 gene is highlighted in red.
(C) Histonemodification profiles in theCD34 gene locus (chr1:206,110,000-206,170,000) in CD133+ andCD36+ cells. The position and direction of transcription of
the CD34 gene are indicated below the panel. The coordinate of the annotated TSS is indicated by the vertical orange line.
(D) Histone modification profiles in the CD36 gene locus (chr7:80,090,000-80,170,000) in CD133+ and CD36+ cells. The position and direction of transcription of
the CD34 gene are indicated below the panel. The vertical orange line indicates the annotated TSS, and the vertical pink line indicates the actual TSS.Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc. 85
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Figure 4. Correlation between Changes in Histone Modification and Gene Expression during Differentiation from CD133+ to CD36+ Cells
The fold changes in both expression level and histone modification level were calculated for each gene during differentiation. The genes were grouped into
100 gene sets according to their expression changes, and the changes were averaged for each set of 100 genes (one dot in the figure); the histone modification
changes were then averaged for the same sets of 100 genes. The y axis indicates the fold change (log10 scale) of histonemodification in the promoter region (A) or
gene body region (B). The x axis indicates that the fold change in expression levels. The clear gaps in some figures are due to cutoff thresholds of histone
modification islands.modifications in the promoter and genebody regionsduringdiffer-
entiation of CD133+ cells to CD36+ cells (Figure 4). The x axis indi-
cates the changes of gene expression level, and the y axis repre-
sents the changes of the number of reads on the histone
modification islands detected in the promoter (Figure 4A) and tran-
scribed regions (Figure 4B). In the promoter region, the H3K4me3
modification change positively correlated with gene expression
change, whereas H3K27me3 inversely correlated with gene
expression and no clear correlation was observed for other modi-86 Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc.fications (Figures 4A). However, in the gene body region, in
addition to the positive correlation with H3K4me3 and negative
correlation with H3K27me3, gene expression showed positive
correlation with all other modifications except H3K9me3 and
H2A.Z (Figure 4B). A positive correlation was detected between
gene expression change and changes in Pol II levels in both the
promoter and gene body regions.
To examine the changes of histone modifications in specific
genegroups,weseparated thegenes into four groupsdepending
Cell Stem Cell
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Figure 5. Gene Activation and Repression during HSC Differentiation Are Associated with Changes in Histone Modifications
Histone modification profiles in induced (A) and repressed (B) genes during differentiation of CD133+ cells (red) to CD36+ cells (green). The tag density for
modifications (see the Supplemental Data for detail) is shown across the gene bodies as well as 5 kb 50 and 30 of the gene bodies.on their expression patterns during differentiation from CD133+
to CD36+ cells: (1) always expressed (9196 genes), (2) induced
(306 genes), (3) repressed (934 genes), and (4) always silent
(7420 genes). The modification profiles aligned relative to TSSs
demonstrated similar patterns for always-expressed genes
between CD133+ and CD36+ cells for all modifications (Fig-
ure S10A). The most interesting changes of modification profiles
were observed for the induced and repressed gene groups. The
active marks including H3K4me1, H3K9me1, H3K27me1,
H3K36me3, and H4K20me1 were markedly increased, whereas
the repressive mark H3K27me3 was decreased in the induced
genes in CD36+ cells (Figure 5A). In contrast, opposite changes
of the profileswere observed for the repressed genes (Figure 5B).
H3K4me3 and H2A.Z levels, mainly in the promoter region, ex-
hibited modest changes according to expression patterns,
whereas Pol II showed significant changes in both promoter
and gene body regions in correspondence to expressionpatterns. We also observed interesting changes in the always-
silent genes. Even though these genes were not expressed in
either CD133+ or CD36+ cells, the levels of H3K4me3, H2A.Z,
and Pol II in promoter regions and H3K4me1, H3K9me1, and
H3K36me3 in either promoter or gene body regions were
decreased after differentiation (Figure S10B). It is noteworthy
that the level of H4K20me1 increased, which behaved differently
from other active marks. These data suggest that the nonex-
pressedgenesbecomestably silencedby losing activemodifica-
tions in differentiated cells.
Distinct Chromatin-Modification Patterns of Bivalent
Genes in CD133+ and CD36+ Cells
Although bivalent domains identified in ESCs can be resolved to
monovalent modification after differentiation (Azuara et al., 2006;
Bernstein et al., 2006; Mikkelsen et al., 2007), very little is known
about the underlying mechanism controlling the fate of theCell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc. 87
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2910 bivalent promoters in CD133+ cells and examined the pres-
ence of other modifications and Pol II at these promoters. The
analysis revealed that many of them were also associated with
H2A.Z (2072; 71%), H3K4me1 (574; 20%), H3K9me1 (750;
26%), and H4K20me1 (886; 30%) (Table S4). Comparison of
the histone modification profiles of the bivalent promoters
between CD133+ and CD36+ cells indicates that H3K4me3
markedly decreased in CD36+ cells (Figure S11). Interestingly,
we also observed a remarkable increase of H4K20me1 (Figur-
e S11H) and modest increase of H3K9me3, H3K27me1, and
H3K4me1 (Figures S11E, S11D, S11B) as well as modest
decrease of H2A.Z (Figure S11I) in CD36+ cells. However, we
did not observe a significant global change in H3K27me3 levels
(Figure S11C). To reveal gene-specific changes, we examined
themodifications of each bivalent gene before and after differen-
tiation. This analysis revealed that, among the 2910 bivalent
genes in HSCs/HPCs, 693 (24%) genes remained bivalent, 1549
(53%) genes lost H3K4me3, 541 (19%) genes lost H3K27me3,
and 127 (4%) genes lost both H3K4me3 and H3K27me3 after
differentiation into CD36+ cells. Next, we examined changes of
other modifications in these four groups of bivalent genes
upon differentiation of CD133+ into CD36+ cells. For the genes
that lost H3K27me3, increased levels of H3K4me1, H3K9me1,
H3K27me1, H3K36me3, and H4K20me1 were detected in the
gene body region, while no significant increases in H3K4me3
and H2A.Z were detected (Figure 6A, Figure S12A). Increased
Pol II levels in the transcribed region indicated activation of
these genes in CD36+cells. Indeed, we detected 196 genes
that showed more than 2-fold expression in CD36+ cells,
whereas only 53 showed decreased expression. For the genes
that lost H3K4me3 alone, we detected a remarkable increase
of H4K20me1, modest decrease of H3K4me1 and H3K9me1,
and almost complete loss of H2A.Z, while there was no signifi-
cant change in H3K27me3 (Figure 6B, Figure S12B). A significant
increase of H4K20me1 was also observed for the genes that lost
both H3K4me3 and H3K27me3 (Figure 6C, Figure S12C).
However, we did not find a correlation between the H4K20me1
level in these gene promoters and gene expression (data not
shown), even though H4K20me1 in gene body regions demon-
strated a certain degree of correlation with gene expression
change (Figure S13). For the genes that remained bivalent in
CD36+ cells, only modest changes of chromatin modifications
were observed (Figure 6D, Figure S12D).
The Fate of Bivalent Modifications after Differentiation
Is Linked to Distinct Chromatin-Modification Patterns
in HSCs/HPCs
To identify the chromatin-modification differences between the
bivalent genes that loseeitherH3K4me3orH3K27me3,weexam-
ined each of the bivalent promoters for association with other
modifications and Pol II in CD133+ cells (Figure 7, Table S4). We
find that H2A.Z was associated with 87% of the promoters that
lost H3K27me3, whereas it was detected at only 59%of the biva-
lent promoters that lost H3K4me3 after differentiation. Similarly,
H3K4me1 and H3K9me1were detected at a much larger fraction
of the bivalent promoters that lost H3K27me3 (46% and 51%,
respectively) than at the promoters that lost H3K4me3 (8% and
15%, respectively). Interestingly, H3K4me1 and H3K9me1 were88 Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc.detected at 27%and 28%, respectively, of the promoters that re-
mained bivalent after differentiation. We also observed a striking
difference for association of RNA Pol II with these different
classes of bivalent genes (34%, 2%, and 14% for the genes
that lost H3K27me3, lost H3K4me3, and remained bivalent,
respectively). These data suggest that the fate of bivalent modifi-
cations after differentiation is linked with chromatin-modification
patterns in the stem cell or progenitor cell stage.
Functional Enhancers of Inducible Genes Are
Associated with Various Modifications before Gene
Induction
Previous large-scale studies have found that potential transcrip-
tional enhancers are associated with various histone modifica-
tion patterns (Barski et al., 2007; Heintzman et al., 2007; Roh
et al., 2005, 2007;Wang et al., 2008). In order to addresswhether
enhancer regions associate with specific histone modifications
prior to gene induction, we examined several genes that were
induced during the differentiation of HSCs/HPCs to erythrocyte
cells. As seen in Figure 3D, the silent CD36 gene was associated
with H3K4me1, H3K27me1, and H3K9me1 in a region about 2 kb
upstream of its TSS in CD133+ cells, suggesting that these
modifications marked a potential enhancer element prior to
gene induction.
The locus control region (LCR) is a critical regulatory element of
the globin genes (Grosveld et al., 1987), which are strongly
induced in CD36+ cells. Indeed, we found that the LCR and the
region upstream of the b-globin gene were associated with high
levels of H3K4me1, H3K9me1, H3K27me1, and H2A.Z, but not
H3K4me3 and H3K27me3 modifications in CD133+ cells, even
though the globin genes were not expressed (Figure 8A). In
contrast, the neutrophil-specific myeloperoxidase (Mpo), which
was primed for expression in HSCs (Ford et al., 1996) and
silenced in CD36+ cells, associated with H3K4me1 and
H3K9me1 in a region upstream of its TSS in CD133+ cells; but
these signals were erased in CD36+ cells (Figure 8B), suggesting
a loss of activation potential after differentiation. These data indi-
cate that themonomethylations includingH3K4me1,H3K27me1,
and H3K9me1 are associated with critical regulatory elements in
the cell stage before their target genes are expressed.
To examine the global changes of these monomethylations
during differentiation, we identified all genes associated with
one of these monomethylations (1321 for H3K4me1, 1475 for
H3K9me1, and 1106 for H3K27me1), but not with H3K4me3 in
CD133+ cells (Table S5). Our data indicated that most of these
modifications were correlated with each other (Figure S14). Inter-
estingly, 53% of H3K4me1 promoters, 59% of H3K9me1
promoters, and71%ofH3K27me1promoters lost their respective
methylation marks after differentiation into CD36+ cells. Among
the promoters that lost monomethylations, 31%–40% demon-
strated decreased expression, while only 10%–14% showed
increased expression. Together, these data suggest that these
monomethylations in HSCs/HPCs may maintain the activation
potential of a subset of genes required for differentiation.
DISCUSSION
We report here the generation of high-resolution genome-wide
maps of eight histone modifications as well as histone variant
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Figure 6. Distinct Histone Modification Changes Are Associated with Different Fates of the Bivalent Genes
Histone modification profiles for the bivalent genes that lost H3K27me3 (A), H3K4me3 (B), or both H3K27me3 and H3K4me3 (C), or remained as bivalent (D),
during differentiation. H3K4me3, H3K27me3, H4K20me1, H2A.Z, and Pol II profiles are shown here. The profiles for other modifications are shown in Figure S13.H2A.ZandRNAPol II, togetherwithgeneexpressionprofiles in the
human CD133+ HSCs/HPCs and CD36+ erythrocyte precursor
cells. Our data provide information on the epigenetic states of
each cell type and reveal interesting relationships between the
fate of bivalent genes during differentiation and their association
with several monomethylations in the stem/progenitor cell stage.
The Fate of Bivalent Domains during Differentiation
Is Linked to Chromatin-Modification Patterns
at HSC/HPC Stage
It has been suggested that HSCs and HPCs are primed for the
potential of differentiation into multiple lineages by coexpressionof various transcription factors, growth factors, and their recep-
tors involved in these lineages prior to the commitment to any
specific lineage (Hu et al., 1997). Indeed, previous gene expres-
sion profiles have confirmed the expression of these critical
factors in HSCs (Ivanova et al., 2002; Ramalho-Santos et al.,
2002; Venezia et al., 2004). Although HSCs exhibit significant
heterogeneity in gene expression between individual cells, coex-
pression of these factors in one single cell has been reported
(Ramos et al., 2006; Warren et al., 2006). Therefore, the multipo-
tentcy of HSCs and HPCs could be related with the expression
potential, albeit at low levels, of many genes involved in the
function and development of multiple lineages. One importantCell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc. 89
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these genes. H3K4me3 has been associated with active genes,
while H3K27me3 has been associated with silent genes in CD4+
T cells (Barski et al., 2007; Roh et al., 2006). We previously re-
ported that the coexistence of H3K4me3 and H3K27me3 is
generally correlated with reduced levels of gene expression in
CD4+ T cells (Barski et al., 2007; Roh et al., 2006; Wang et al.,
2008) and proposed that the coexistence of these two appar-
ently counteracting modifications provides a mechanism of
either gene activation or repression through a shift in their
balance (Roh et al., 2006; Wang et al., 2008). Studies using
ESCs suggest that bivalent modifications maintain the activation
or silencing potential of critical differentiation genes (Azuara
et al., 2006; Bernstein et al., 2006). It is known that some of the
bivalent genes can lose H3K4me3 while others can lose
H3K27me3 during differentiation. However, it is not clear what
controls the fate choice of the bivalent genes. The data we report
here indicate that numerous genes involved in the development
and differentiation of multiple lineages are associated with both
the repressive mark H3K27me3 and the active mark H3K4me3
in HSCs/HPCs. We found that 19% of the bivalent genes lost
H3K27me3 and became activated after differentiation into
CD36+ cells. Interestingly, a large fraction of these genes were
associated with H3K4me1 and H3K9me1 modifications in the
HSC/HPC stage and also bound with RNA Pol II, suggesting
that they were poised for activation. In contrast, the association
of these monomethylations with the bivalent promoters, which
lost H3K4me3 after differentiation, was decreased dramatically
A B
C D
Figure 7. The Fate of Bivalent Genes after Differentiation Is Linked to
the Chromatin-Modification Patterns in HSCs/HPCs
The fraction of the bivalent genes associated with H2A.Z, H3K4me1,
H3K9me1, H4K20me1, and Pol II was indicated for those that lost
H3K27me3 (A), lost H3K4me3 (B), lost both (C), or remained bivalent (D) after
differentiation.90 Cell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc.in the HSC/HPC stage; in addition, almost no Pol II was detected
in these promoters. These results are consistent with a model in
which the fate of bivalent genes during differentiation is
controlled by epigenetic modifications including various mono-
methylations that occur in the HSC/HPC stage.
Genome-wide Silencing of the Genes Maintaining
the Multipotent Potential of HSCs/HPCs
The loss of multipotency and commitment to differentiation is
accompanied by the induction of genes involved in one particular
lineage and the silencing of genes required for other lineages.
We found that only 24% of the 2910 bivalent genes remained
bivalent after differentiation. Instead, most bivalent promoters
(53%) lost H3K4me3 after differentiation. Even those that re-
mained bivalent were associated with lower levels of H3K4me3
in CD36+ cells. These results indicate that the differentiation
into CD36+ cells is accompanied by a genome-wide silencing
of the genes involved in the development and differentiation of
other lineages and that the silent states are locked off by a switch
of epigenetic modifications.
Epigenetic Signals on Critical Transcriptional
Regulatory Elements
H3K4 methylation has been detected at silent loci in ESCs and
differentiated cells (Barski et al., 2007; Bernstein et al., 2006;
Guenther et al., 2007; Meissner et al., 2008; Mikkelsen et al.,
2007; Roh et al., 2006; Wang et al., 2008; Weber et al., 2007).
The presence of H3K4me3 at inactive genes has been proposed
to be a memory for past transcriptional activity based on studies
performed in yeast (Ng et al., 2003). However, we detected
H3K4me3 signals at numerous genes that are inactive in
HSCs/HPCs but required for functions of multiple lineages other
than erythrocytes. Interestingly, upon commitment to the eryth-
rocyte pathway, the H3K4me3 signals disappeared from these
genes. These data suggest that the H3K4me3 signal present at
the developmental genes in HSCs/HPCs may not be just
a memory for past transcription but instead may be part of an
epigenetic state that maintains the activation potential of the
genes required for specific differentiation pathways. In addition
to H3K4me3 and H3K27me3 modifications, we also detected
various monomethylations as well as H2A.Z in these genes.
H2A.Z typically colocalizes with H3K4me3 near the TSSs,
whereas monomethylations can be detected near TSSs or well
within the gene body. A large-scale analysis of histone modifica-
tion patterns in 1%of the human genome has revealed that func-
tional enhancers are marked by H3K4me1 (Heintzman et al.,
2007). Our genome-wide analyses of histone modifications in
human T cells have indicated that enhancers can be associated
with histone acetylation (Roh et al., 2005, 2007), various histone
methylations including H3K4me1, H3K4me3, H3K9me1, and
H3K27me1, and histone variant H2A.Z (Barski et al., 2007;
Wang et al., 2008). However, it is not clear whether the enhancers
required for differentiation genes, which are not active in stem
and progenitor cells, are marked with histone modifications prior
to gene activation. Several lines of evidence suggest that this is
the case. For example, the CD36 gene promoter is associated
with H3K4me1, H3K9me1, and H3K27me1 in HSCs/HPCs,
where it was not expressed. The LCR, which is required for
efficient induction of the globin genes in erythrocytes, is also
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these critical regulatory elements are epigenetically modified
long before gene expression. Consistent with this, it was reported
recently that H3K4me2 marks a subset of developmentally
poised hematopoietic genes (Orford et al., 2008). It is curious
that no H3K4me3 signals were detected at either the promoter
or enhancer regions of these genes in HSCs/HPCs, suggesting
that the monomethylation of H3K4, H3K9, and H3K27 may be
earlier epigenetic signals for gene induction. This idea is also
consistent with the observation that these modifications are
detected in the paternal pronucleus at fertilization of an egg
when the paternal genome is decondensed to prepare for tran-
scriptional activation, whereas H3K4me3 and H3K27me3 only
become detectable later after DNA replication (Lepikhov and
Walter, 2004; Santos et al., 2005).
In summary, we have provided high-resolution genome-wide
maps for eight histone modifications, histone variant H2A.Z
and RNA Pol II in both HSCs/HPCs and the differentiated
CD36+ cells, an important resource for understanding the tran-
scriptional regulation and epigenetic states of these clinically
important human primary cells. Our data argue that the fate
of bivalent genes during differentiation is programmed by
chromatin modifications including H3K4me1, H3K9me1,
H4K20me1, and H2A.Z at the HSC/HPC stage. In addition to
bivalent genes, our data suggest that the monomethylations
are correlated with the basal level expression of a subset of
differentiation genes in HSCs/HPCs and therefore may be
involved in the maintenance of their activation potential required
for differentiation.
A
B
Figure 8. H3K4me1, H3K9me1, and
H3K27me1 Modifications Mark Critical
Regulatory Regions before Gene Activation
The histone modification profiles at the b-globin
locus (chr11:5,171,954-5,279,020) (A) and MPO
(chr17:53,682,809-53,732,673) (B) genomic re-
gions in CD133+ and CD36+ cells are displayed.
The critical promoter or enhancer regions are
highlighted in red.
EXPERIMENTAL PROCEDURES
Isolation of CD133+ Cells and
Differentiation into CD36+ Cells
Multipotent HSCswere collected from the blood of
healthy volunteers following mobilization with G-
CSF and AMD3100 (NHLBI protocol 04-H-0179);
CD133+ HSCs cells were isolated from apheresis
products using immunomagnetic beads specific
for CD133 (Miltenyi CliniMacs system) and stored
in liquid nitrogen. For FACS analysis of cell surface
markers and ChIP-Seq analysis of histone modifi-
cations, the cells were recovered in serum-free
long-term culture medium (LTCM) containing
100 ng/ml Flt3-ligand (FL), 100 ng/ml megakaryo-
cyte growth and development factor (MGDF),
100 ng/ml stem cell factor (SCF), and 10 ng/ml
granulocyte colony-stimulating factor (G-CSF) at
37C in 5% CO2 for 12 hr. For differentiation into
CD36+ cells, the CD133+ cells were suspended at
104 cells/ml in maintenance media that was
prepared by 1:5 dilution of BIT 9500 (StemCell
Technologies, Cat# 09500) in AMEM (Mediatech, Cat# 10-022-CV) for a final
concentration of 10mg/ml BSA, 10 mg/ml rh insulin, and 200 mg/ml hTransferrin
and supplemented with 900 ng/ml ferrous sulfate (Sigma, Cat# F8633), 90 ng/
ml ferric nitrate (Sigma, Cat# F8508), 106M hydrocortisone (Sigma, Cat#
H6909), 100 ng/ml rh SCF (PEPROTECH, Cat# 300-07), 5 ng/ml rh IL-3
(PEPROTECH, Cat# 200-03), and 3 IU/ml rh Epo (StemCell Technologies,
Cat# 02625). The cells were incubated at 37C in a 5% CO2/95% air atmo-
sphere for 9–11 days, followed by FACS analysis for the presence of CD36+
cells.
Chromatin from CD133+ and CD36+ cells was prepared using micrococcal
digestion as described (Barski et al., 2007). 10 3 106 cells were used for
each ChIP-Seq analysis.
The flow cytometry analysis of CD133+ and CD36+ cells was performed
using the following antibodies from BD PharMingen: CD34-PE (#555822),
CD36-PE (#555455), CD36-FITC (#555454), CD38-PE (#555460), CD177-APC
(#341096), CD90-FITC (#555595), HLA-DR (#555812),CD43-APC (#560198),
and CD71-PE-Cy5 (#551143). CD133-APC (#130-090-854) was from MACS.
Gene Expression Analysis
Total RNAs from the CD133+ and CD36+ cells were isolated using the RNeasy
kit (QIAGEN, Cat# 74104) and subjected to DNA microarray analysis for gene
expression profiles using the HG-U133 Plus 2.0 chip (Affymetrix, Cat#
900466). Two replicates were obtained, and the average of the two values
obtained for each probe ID was taken as the expression value of that probe
ID. Gene expression categorization by the absent and present calls using
MAS5.0 algorithm provided by Affymetrix was performed. Genes with conflict-
ing calls in the two replicates were ignored. The expression data are provided
in Table S6.
ChIP-Seq and Data Analysis
The ChIP-Seq analysis was performed as described previously (Barski et al.,
2007). The sequence reads and expression data have been deposited
in the NCBI Short Reads Archive (GSE12646). The BED files can beCell Stem Cell 4, 80–93, January 9, 2009 ª2009 Elsevier Inc. 91
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Chromatin Signatures in Human HSCsdownloaded from the website (http://dir.nhlbi.nih.gov/papers/lmi/
epigenomes/hghscmethylation.html). Detailed strategies for data analysis
can be found in the Supplemental Data.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, six tables, and fourteen figures and can be found
with this article online at http://www.cell.com/cell-stem-cell/supplemental/
S1934-5909(08)00582-1.
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